VN-0200
/ Daiichi Sankyo
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
April 21, 2025
Immunogenicity, safety, and tolerability of a β-glucan-CpG-adjuvanted respiratory syncytial virus vaccine in Japanese healthy participants aged 60 to 80 years: A phase 2, randomized, double-blind, dose-finding study.
(PubMed, Hum Vaccin Immunother)
- "There were no serious vaccine-related treatment-emergent adverse events (TEAEs) or vaccine-related TEAEs leading to death. All antigen/adjuvant dose combinations of VN-0200 were well tolerated and elicited an increase in anti-RSV/A and anti-RSV/B neutralization activity from baseline to Day 29 and Day 57."
Clinical • Journal • P2 data • Respiratory Diseases • Respiratory Syncytial Virus Infections • IFNG
February 29, 2024
A Dose Finding Study of VN-0200
(clinicaltrials.gov)
- P2 | N=342 | Completed | Sponsor: Daiichi Sankyo | Active, not recruiting ➔ Completed | Trial primary completion date: Dec 2023 ➔ Apr 2023
Trial completion • Trial primary completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections
February 21, 2023
A Dose Finding Study of VN-0200
(clinicaltrials.gov)
- P2 | N=340 | Active, not recruiting | Sponsor: Daiichi Sankyo Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • IFNG
October 31, 2022
A Dose Finding Study of VN-0200
(clinicaltrials.gov)
- P2 | N=340 | Recruiting | Sponsor: Daiichi Sankyo Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • IFNG
September 21, 2022
A Dose Finding Study of VN-0200
(clinicaltrials.gov)
- P2 | N=340 | Not yet recruiting | Sponsor: Daiichi Sankyo Co., Ltd.
New P2 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • IFNG
December 22, 2021
Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects
(clinicaltrials.gov)
- P1; N=48; Completed; Sponsor: Daiichi Sankyo Co., Ltd.; Active, not recruiting ➔ Completed
Clinical • Trial completion • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • IFNG
1 to 6
Of
6
Go to page
1